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Abstract: Diabetic macular edema (DME) is a leading cause of vision loss in older Americans. 
Thermal laser treatment remains the mainstay of treatment for DME. Recently, alternative 
primary treatments for DME have been evaluated. These treatments include intravitreal injec-
tions of steroids as well as pharmaceuticals containing antibodies against vascular endothelial 
growth factor (VEGF). Surgical treatment has been shown to be appropriate in selected cases. 
We review the evidence and scientiﬁ  c rationale for various primary treatment options in patients 
with DME. Regular and timely ophthalmologic evaluation remains crucial to recognition and 
treatment of macular edema in diabetic patients.
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Introduction
Diabetes mellitus affects approximately 20% of American adults over the age of 60, 
and diabetic retinopathy is a leading cause of blindness in older Americans.1 Diabetic 
retinopathy is also impacting younger age groups as the incidence of diabetes rises in 
adolescents and younger adults.2 Diabetic retinopathy is therefore a signiﬁ  cant public 
health problem.1 Because vision loss from diabetic retinopathy is painless and usually 
gradual in onset, ophthalmologic evaluation is necessary to distinguish diabetic reti-
nopathy from other causes of painless vision loss in diabetic patients, such as cataract 
and retinal vein occlusion. Furthermore, diabetic retinopathy may be present before 
vision loss occurs, and progressive retinal damage may be overlooked until the disease 
is advanced. Early diagnosis and prompt medical intervention are important to prevent 
avoidable loss of vision.
The incidence of diabetic retinopathy increases with duration of disease,2 and reti-
nopathy occurs more frequently in patients with poorly controlled diabetes. Co-morbid 
conditions such as hypertension and hypercholesterolemia compound the problem. It 
is therefore imperative that patients with diabetic retinopathy have appropriate man-
agement of both their systemic diseases and their ophthalmic condition.3 A thorough 
review of medical conditions and medications is important, particularly because 
diabetic retinopathy may be exacerbated by systemic medications such as glitazones, 
in which case macular edema may resolve with discontinuation.4
Diabetic retinopathy occurs because the retinal vessels are abnormal, either 
because they proliferate (proliferative retinopathy) or because the vessels are func-
tionally incompetent and leak ﬂ  uid and lipid into the retina. Visual impairment 
occurs when edema affects the central retina or macula (diabetic macular edema, or 
DME). Macular edema is reversible in the early stages but chronic edema may lead 
to irreversible changes in the retina. In a large cohort study, diabetics with macular 
edema had a 50% prevalence of visual impairment and a 20% prevalence of blind-
ness, compared to 16% and 4% respectively in diabetic patients without macular 
edema.5 Figures 1 and 2 contrast the ophthalmic features of macular edema with a 
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Thermal laser treatment has been and remains the 
mainstay for treating macular edema. However, several 
alternative treatments have emerged over the last few years. 
Most of these treatments are currently used as second-line 
therapy for patients with macular edema refractory to thermal 
laser, but an increasing number of studies have examined 
ﬁ  rst-line use of these alternative therapies. This paper pro-
vides an overview of primary treatment options for diabetic 
macular edema, along with the rationale for each treatment 
modality.
Thermal laser
Thermal laser is the most established primary treatment for 
diabetic macular edema. Laser treatment is delivered at a slit 
lamp using a contact lens on the cornea. Since the sensory 
retina is transparent, the laser energy is absorbed by vascular 
structures within the retina or by the pigmented epithelium 
immediately behind the sensory retina. Focal laser spots 
may be applied to microaneurysms in order to stop leakage 
of ﬂ  uid. A grid pattern of laser spots also may be applied 
lightly to the pigmented epithelium in areas of more diffuse 
edema. The pigmented epithelium functions as a pump to 
remove ﬂ  uid from the retina, and stimulation with laser spots 
is thought to stimulate pump function and thereby decrease 
retinal edema.6
The Early Treatment of Diabetic Retinopathy Study 
(ETDRS), a large randomized controlled trial completed 
in 1985, demonstrated that prompt laser treatment of the 
macula reduced the frequency of vision loss by 50% in 
diabetic patients with macular edema compared to untreated 
control subjects.3 In addition, almost half of the patients 
with poor vision initially demonstrated some improved 
Figure 1a Color photograph of a normal macula.   The normal retinal vasculature is visible against a relatively homogeneous background, with the central macula (fovea) demonstrating 
normal pigmentary differences compared to the surrounding tissues.Clinical Interventions in Aging 2009:4 103
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vision at three years of follow-up. Patients typically need 
more than one laser treatment and long term follow-up is 
needed so that recurrent edema can be managed in a timely 
manner.
Steroids
Diabetic macular edema is caused by a cascade of 
vascular permeability factors that include the production 
of interleukin-6 (IL-6) and vascular endothelial growth 
factor (VEGF). IL-6 and VEGF are present in higher 
concentrations in eyes with diabetic retinopathy and 
steroid administration reduces the concentration of these 
factors with concurrent clinical improvement of macular 
edema.7,8
There are two ways to deliver steroids into the vitreous 
cavity. The ﬁ  rst is by direct injection into the vitreous cavity 
(intravitreal injection); triamcinolone is the most frequently 
used steroid for this purpose. In a recent prospective 
randomized study of more than 100 patients, intravitreal 
injection of triamcinolone improved visual acuity and 
decreased retinal thickness compared to baseline, and neither 
endpoint was signiﬁ  cantly different compared to macular 
laser treatment alone or laser combined with triamcinolone.9 
These ﬁ  ndings suggest that triamcinolone treats DME at least 
as well as laser alone over six months of follow-up, although 
some patients in the study had received previous laser treat-
ment.9 Intravitreal triamcinolone has also been successfully 
combined with macular laser treatment as the initial therapy 
for diabetic macular edema.10,11 In addition, numerous studies 
have shown that intravitreal steroids reduce macular edema 
in cases that are refractory to laser treatment, although 
visual acuity does not consistently improve in these cases, 
Figure 1b Optical coherence tomography image of a normal macula.   The layers of the sensory retina appear homogeneous throughout, with a normal foveal depression.
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probably due to permanent damage to retinal photoreceptors 
by chronic edema.12,13
Side effects of intravitreal steroids include accelerated 
development of cataracts as well as elevated intraocular pres-
sure that may lead to glaucomatous damage to the optic nerve. 
These complications may require surgical correction.12
A second way to deliver intravitreal steroids is by 
sustained-release steroid implants. The Posurdex implant 
(Dexamethasone Posterior Segment Drug Delivery System; 
Allergan Inc, Irvine, CA, USA) releases dexamethasone into 
the vitreous cavity for up to six months, while the Retisert 
implant (ﬂ  uocinolone acetonide intravitreal implant; Bausch 
and Lomb Inc, Rochester, NY, USA) releases ﬂ  uocinolone 
acetonide. Both implants have been shown to improve 
vision in patients with diabetic macular edema, but both 
are relatively expensive and carry side effects similar to 
intravitreal triamcinolone injections.13
Anti-VEGF therapies
Since VEGF contributes to the development of macular 
edema, attention has recently focused on intravitreal 
injections of anti-VEGF antibodies. Antibodies delivered 
by intravitreal injection bind to VEGF and thereby decrease 
downstream effects on vascular leakage. Anti-VEGF 
antibodies were ﬁ  rst used to treat patients with exudative age-
related macular degeneration (AMD) with dramatic beneﬁ  cial 
results. Because of these beneﬁ  ts, anti-VEGF antibodies are 
now being evaluated in the treatment of macular edema.
Three drugs are currently in use. Bevacizumab (Avastin; 
Genentech, San Francisco, CA) was approved by the FDA 
Figure 2a Color photograph of a macula exhibiting diabetic macular edema. Microaneurysms and intra-retinal hemorrhages are visible as red spots. Retinal thickening is visible 
as a loss of granularity combined with subtle changes in coloration and is best visualized in stereo using slit lamp biomicroscopy. Lipid exudates are visible as yellow streaks 
or spots, often distributed in a circinate pattern around leaking microaneurysms.Clinical Interventions in Aging 2009:4 105
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for intravenous use in cancer patients. This drug has been 
used off-label as an intravitreal injection, ﬁ  rst for AMD, and 
subsequently for a variety of other ocular diseases including 
macular edema.14 Ranibizumab (Lucentis; Genentech, San 
Francisco, CA) is FDA-approved for intravitreal injection 
in patients with AMD, and has been used off-label for 
other ocular diseases including diabetic macular edema.15 
Pegaptanib (Macugen; OSI Pharmaceuticals, Melville, NY) 
was FDA-approved for intravitreal injection in patients with 
AMD before the advent of ranibizumab and bevacizumab. 
Pegaptanib has fallen out of favor for use in AMD patients 
but has been studied in patients with diabetic macular 
edema.
Two prospective randomized controlled trials recently dem-
onstrated greater improvements in visual acuity, albeit with just 
trhee months follow-up, in patients receiving intravitreal beva-
cizumab compared to controls receiving laser treatment.16,17 
Bevacizumab has also produced improvements in visual acuity 
and retinal thickness in patients who are refractory to initial 
laser treatment.18,19 The initial results are promising but follow 
up is limited. Long-term follow-up may help to establish the 
utility of intravitreal bevacizumab for diabetic macular edema, 
as well as determine the regimen of treatment to maintain vision 
and prevent recurrence.
Data regarding ranibizumab for diabetic macular edema 
is more limited, likely due to the high price of ranibizumab 
compared to bevacizumab. Two small prospective studies 
demonstrated maintenance or improvement of vision in 
patients treated primarily with ranibizumab.20,21
Pegaptanib was shown in a Phase II randomized 
controlled trial to decrease vision loss and increase vision 
gain compared to a sham medication, with a decreased need 
for subsequent photocoagulation.22 However, pegaptanib was 
not directly compared to thermal laser in this study.
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Figure 2b Optical coherence tomography image of a macula exhibiting diabetic macular edema. Thickening of the sensory retina is evident along with typical focal cystoid 
changes, seen as optically clear cavities within the retina. The foveal depression is lost due to edema.Clinical Interventions in Aging 2009:4 106
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Side effects of intravitreal anti-VEGF injections are rare 
and include retinal detachments, which are most likely due to 
the injection procedure itself rather than the pharmaceutical 
compound (the risk of retinal detachment is common to other 
intravitreal injections such as triamcinolone). Similarly, 
endophthalmitis is a rare complication of intravitreal injection 
and is likely related to the injection itself rather than speciﬁ  c 
pharmaceutical characteristics.23 Intravitreal bevacizumab 
and ranibizumab do not result in signiﬁ  cant elevations of 
intraocular pressure nor have they been shown to accelerate 
cataract formation to any appreciable degree.
Vitrectomy
Pars plana vitrectomy is a surgical procedure in which the 
vitreous gel is removed from the eye. Some cases of diabetic 
macular edema are associated with vitreous traction on 
the retina. Vitrectomy has been shown in several studies to 
improve vision in patients with traction-associated macular 
edema.24,25 Vitrectomy has also been studied in patients 
without a tractional component, with mixed results.26–28
Conclusion
Early detection of diabetic retinopathy and prompt treatment 
of macular edema are important for preserving vision in the 
diabetic patient. Thermal laser is the mainstay of treatment 
for diabetic macular edema, and strong evidence supports 
the use of laser treatment to decrease progressive vision loss. 
Diabetic eye disease is a major cause of vision loss in working 
age American adults, resulting in hundreds of millions of 
dollars in direct and indirect medical expenses each year.29 
Intravitreal steroid and anti-VEGF injections may be used in 
lieu of or in combination with thermal laser to limit vision 
Figure 2c Fluorescein angiography of a macula exhibiting diabetic macular edema. The retinal vascular arcades are visible along with scattered areas of hyperﬂ  uorescence 
throughout the macula, indicating leakage of ﬂ  uid due to diabetes-induced vascular incompetence.Clinical Interventions in Aging 2009:4 107
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loss and in some cases improve vision. However, data on 
the long term results for these newer modalities is limited. 
The next few years may see a shift in the primary therapy 
of macular edema as more data become available about the 
efﬁ  cacy of intravitreal steroids and anti-VEGF antibodies.
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